Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure



Status:Terminated
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - 90
Updated:4/21/2016
Start Date:July 2013
End Date:November 2013

Use our guide to learn which trials are right for you!

Randomized, Double-Blind, Placebo-Controlled Study To Evaluate D-Ribose For The Treatment Of Congestive Heart Failure

To evaluate the safety and to determine the efficacy of D-ribose for the treatment of
congestive heart failure (CHF) in subjects who have been stabilized following
hospitalization with acute decompensation.

This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center study of
D-ribose administered via peripheral intravenous line for 24 hours to stabilized
hospitalized patients following standard of care treatment for acute decompensation of CHF,
followed by oral dosing of D-ribose three times a daily through the remainder of the
inpatient hospital stay and outpatient period of 3 months. Subjects will complete
Pretreatment Screening procedures only after the Investigator has established that they have
met the pre-specified criteria for stabilization of heart failure, and be randomized to
treatment no more than 7 days after admission to the hospital.

Inclusion Criteria:

- written informed consent and Health Insurance Portability and Accountability Act
authorization, as applicable;

- symptomatic heart failure (NYHA Class II, III or IV) ≥ 30 days prior to current acute
decompensation episode;

- ≥2 of the following signs of acute decompensation: jugular venous distension, rales,
dyspnea, and ≥ 1+ pedal edema;

- admitted to the hospital ≤ 36 hours after initial evaluation;

- discontinued from IV inotropic support ≥ 48 hours prior to Screening;

- initiated Screening when subject has met the following criteria for stabilization:

- exacerbating factors addressed;

- near optimal volume status;

- transition from IV to oral diuretic completed;

- near optimal pharmacologic therapy achieved or intolerance documented;

- completed Screening procedures and been randomized to treatment ≤ 7 days after
hospital admission;

- LVEF ≤ 35% ≤ 12 months prior to Screening.

- if female, ≥ 2 years post-menopausal, surgically sterile, or practicing effective
contraception;

- if female, non-lactating, and if of child-bearing potential, has negative pregnancy
test result at Screening;

- willing to abstain from ribose-containing products during study.

Exclusion Criteria:

- significant medical condition(s) which, in Investigator's judgment, could compromise
subject's welfare or confound study results;

- significant hepatic, renal, or hematologic disorder/dysfunction beyond that expected
from CHF alone;

- Creatinine Clearance <30.0 mL/min at Screening;

- serum potassium level <3.5 milliequivalent per liter or >5.7 milliequivalent per
liter, or a serum sodium level <130 milliequivalent per liter at Screening;

- systolic arterial blood pressure <90 mm Hg at Screening;

- received ultrafiltration during current admission;

- cardiac surgery ≤ 60 days prior to Screening, except for percutaneous intervention;

- planned revascularization procedures, electrophysiologic device or cardiac mechanical
support implantation, cardiac transplantation, or other cardiac surgery ≤ 90 days
after study enrollment;

- functional mitral valve regurgitation > moderate severity;

- aortic regurgitation of at least moderate severity;

- hemodynamically significant primary cardiac valvular disease;

- myocardial infarction ≤ 30 days prior to Screening;

- Acute Coronary Syndrome ≤ 30 days prior to Screening;

- known or suspected right-to-left, bi-directional, or transient right-to-left cardiac
shunt;

- sustained ventricular tachycardia or ventricular fibrillation ≤ 30 days prior to
Screening, unless automatic implantable cardioverter defibrillator is present;

- atrial fibrillation within the past year;

- CHF related to tachyarrhythmias or bradyarrhythmias;

- CHF due to uncorrected thyroid disease, active myocarditis, or known amyloid
cardiomyopathy;

- angina at rest or with slight exertion and/or unstable angina;

- diagnosed with hypertrophic cardiomyopathy;

- cerebrovascular accident ≤ 6 months prior to Screening;

- cardiogenic shock at any time from initial evaluation to randomization;

- on cardiac mechanical support;

- biventricular pacer placement ≤ 60 days prior to Screening or needed pacemaker
placement during the current admission;

- refractory, end-stage heart failure;

- type I or type II diabetes;

- history of pancreatitis;

- current systemic infection;

- urinary tract obstruction;

- morbidly obese (weight > 159 kg [350 lbs] or BMI >42 kg/m2);

- active malignancy at Screening. [Treatment for basal cell or stage 1 squamous cell
carcinoma, or cervical carcinoma in situ allowed];

- terminally ill or has moribund condition;

- history of irritable bowel syndrome, inflammatory bowel disease, ischemic colitis,
vascular intestinal atherosclerosis, previous bowel resection, impaction, or similar
gastrointestinal conditions;

- currently taking Kayexalate® (sodium polystyrene sulfonate);

- allergic reaction to Optison™ or Definity® or any of their components.
We found this trial at
21
sites
Columbus, Georgia 31904
1901
mi
from 91732
Columbus, GA
Click here to add this to my saved trials
621 West Lombard Street
Baltimore, Maryland 21201
(410) 706-7101
University of Maryland, Baltimore Welcome to the University of Maryland, Baltimore (UMB) founded in 1807...
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
1000 W Carson St
Torrance, California 90502
23
mi
from 91732
Torrance, CA
Click here to add this to my saved trials
2615
mi
from 91732
Auburn, ME
Click here to add this to my saved trials
1 Genesys Pkwy
Grand Blanc, Michigan 48439
(810) 606-5000
Genesys Regional Medical Center Genesys Health System, a member of Ascension Health, is a group...
1941
mi
from 91732
Grand Blanc, MI
Click here to add this to my saved trials
Houston, Texas 77030
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
200 Hawkins Dr,
Iowa City, Iowa 52242
866-452-8507
University of Iowa Hospitals and Clinics University of Iowa Hospitals and Clinics—recognized as one of...
1528
mi
from 91732
Iowa City, IA
Click here to add this to my saved trials
Kenner, Louisiana 70065
1645
mi
from 91732
Kenner, LA
Click here to add this to my saved trials
Long Beach, California 90801
21
mi
from 91732
Long Beach, CA
Click here to add this to my saved trials
Macon, Georgia 31201
1974
mi
from 91732
Macon, GA
Click here to add this to my saved trials
Memphis, Tennessee 38138
1586
mi
from 91732
Memphis, TN
Click here to add this to my saved trials
Modesto, California 95350
299
mi
from 91732
Modesto, CA
Click here to add this to my saved trials
Muncie, Indiana 47303
1835
mi
from 91732
Muncie, IN
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
2432
mi
from 91732
New York, NY
Click here to add this to my saved trials
2423
mi
from 91732
Newark, NJ
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73210
1164
mi
from 91732
Oklahoma City, OK
Click here to add this to my saved trials
2900 W Queen Ln
Philadelphia, Pennsylvania 19129
(215) 991-8100
Drexel University College of Medicine Drexel University College of Medicine represents the consolidation of two...
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
101 Nicolls Rd
Stony Brook, New York 11794
(631) 444-4000
Stony Brook University Medical Center Stony Brook Medicine expresses our shared mission of research, clinical...
2503
mi
from 91732
Stony Brook, NY
Click here to add this to my saved trials
Sylmar, California 91342
28
mi
from 91732
Sylmar, CA
Click here to add this to my saved trials
Teaneck, New Jersey 07666
2431
mi
from 91732
Teaneck, NJ
Click here to add this to my saved trials
Toronto, Ontario
2159
mi
from 91732
Toronto,
Click here to add this to my saved trials